Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05197790 · ClinicalTrials.gov registry record · NA
Functionality of the Pulse Oximeter and Accelerometer Portions of a Novel Wearable Device
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT05197790: Completed NA study, sponsored by University of Pennsylvania.
NCT05197790 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05197790, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to asses the function of an oxygen sensor and the movement sensor in a novel device prototype.
Primary Outcome
Dove device will be analyzed against FDA approved SpO2 and Skin tone will be incorporated as a factor of SpO2 function to ensure the device can be reasonably detect hypoxia. At each time point, the difference between the device and the FDA approved standard will be calculated. Mean average error will be used as a single summary statistic, and Bland-Altmann analysis will be used to graphically and numerically represent the limits of agreement.
Interventions
- DEVICE FDA approved pulse oximeter and DOVE device prototype
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-05-20 |
| Est. Completion | 2024-12-28 |
| Phase | NA |
What the finished NCT05197790 record still lists
NCT05197790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which FDA approved pulse oximeter and DOVE device prototype is the first listed.
NCT05197790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05197790 about?
NCT05197790 is a clinical study titled "Functionality of the Pulse Oximeter and Accelerometer Portions of a Novel Wearable Device". The purpose of this study is to asses the function of an oxygen sensor and the movement sensor in a novel device prototype.
What is the current status of trial NCT05197790?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2022-05-20. Estimated completion is 2024-12-28.
What interventions are being tested in trial NCT05197790?
The interventions under investigation include: FDA approved pulse oximeter and DOVE device prototype (DEVICE).
Who is sponsoring clinical trial NCT05197790?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05197790's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI